(Q24241541)

1

0 references

Marina Romano

2

0 references

Liliana Patrucco

4

0 references

Edgardo Cristiano

Cochrane Database of Systematic Reviews

5

0 references

publication date

21 January 2009

0 references

published in

0 references

cites work

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Natural history of multiple sclerosis: a unifying concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Primary and transitional progressive MS: a clinical and MRI cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Diagnostic criteria for primary progressive multiple sclerosis: a position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

Primary progressive multiple sclerosis : current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

Primary-progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

Primary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006643.PUB2

7 January 2021